专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070231385A1 Controlled Release Pharmaceutical Composition and a Process for Preparing the Same 审中-公开
标题翻译：控制释放药物组合物及其制备方法
公开(公告)号：US20070231385A1
公开(公告)日：2007-10-04
申请号：US10574320
申请日：2004-09-29
申请人： Himadri Sen , Suryakumar Jayanthi , Vineeth Raghavan , Ganga Arra
发明人： Himadri Sen , Suryakumar Jayanthi , Vineeth Raghavan , Ganga Arra
IPC分类号： A61K9/24 , A61K31/505 , A61K31/535 , A61K31/551 , A61K47/38
CPC分类号： A61K9/209
摘要： A three-drug antiretrovial pharmaceutical composition having a selective combination of a controlled release active formulation and an immediate release active formulation for once daily administration. The composition provides desired dosages of the actives lamivudine, zidovudine or pharmaceutically acceptable derivatives thereof, and the immediate release formulation including at least one selective Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI), preferably nevirapine or a pharmaceutically acceptable derivative thereof along with pharmaceutically acceptable excipients. The once daily composition would favour patient compliance and effective treatment. A method of reducing the pill burden in a patient suffering from HIV infection and/or Acquired Immunodeffieciency Syndrome by administering a once daily dose of the three-drug antiretroviral pharmaceutical composition.
摘要翻译：一种三药抗逆转录药物组合物，其具有控释活性制剂和立即释放活性制剂的选择性组合，每日一次给药。所述组合物提供所需剂量的拉米夫定，齐多夫定或其药学上可接受的衍生物，并且立即释放制剂包括至少一种选择性非核苷逆转录酶抑制剂（NNRTI），优选奈韦拉平或其药学上可接受的衍生物以及药学上可接受的赋形剂。每天一次的组合将有利于患者的顺应性和有效的治疗。一种通过施用一日剂量的三药抗逆转录病毒药物组合物来减少患有HIV感染和/或获得性免疫缺陷综合征的患者的药丸负担的方法。

2. 发明申请

US20070154408A1 INHALABLE BIODEGRADABLE MICROPARTICLES FOR TARGET-SPECIFIC DRUG DELIVERY IN TUBERCULOSIS AND A PROCESS THEREOF 审中-公开
标题翻译：用于靶向特异性药物输送在管腔内的可生物降解的微生物及其过程
公开(公告)号：US20070154408A1
公开(公告)日：2007-07-05
申请号：US11684559
申请日：2007-03-09
申请人： Himadri Sen , Suryakumar Jayanthi , Rakesh Sinha , Rolee Sharma , Pavan Muttil
发明人： Himadri Sen , Suryakumar Jayanthi , Rakesh Sinha , Rolee Sharma , Pavan Muttil
IPC分类号： A61K9/14
CPC分类号： A61K9/0075 , A61K9/0053 , A61K9/1647 , A61K31/00 , A61K31/445 , A61K31/455
摘要： The present invention relates to a biodegradable microparticle composition useful for the target specific drug delivery to manage pulmonary tuberculosis, said composition comprising two anti-tuberculosis drugs, and a biodegradable polymer for drug delivery in a ratio of about 1:2 to 2:1, wherein the anti-tubercular drugs are in the ratio of 1:2 to 2:1, also, a process for the preparation of the composition, and lastly, a method of treating pulmonary tuberculosis in a subject, said method comprising administering by inhalation alone or in combination with oral route, pharmaceutically effective amount of the composition to the subject in need thereof, wherein the dosage for inhalation is ranging between 0.5 to 10 mg/kg body weight/day and that for oral route is ranging between 4 to 32 mg/kg body weight/day.
摘要翻译：本发明涉及可用于目标特异性药物递送以管理肺结核的可生物降解的微粒组合物，所述组合物包含两种抗结核药物和用于药物递送的生物可降解聚合物，其比例为约1:2至2:1，其中抗结核药物的比例为1:2至2:1，也是制备组合物的方法，最后是治疗受试者肺结核的方法，所述方法包括单独给药或与口服途径组合的药物有效量的组合物与有需要的受试者组合，其中吸入剂量为0.5至10mg / kg体重/天，口服途径的范围为4至32mg / kg体重/天。

3. 发明申请

US20090208575A1 Pharmaceutical Composition Of Acid Labile Substances 审中-公开
标题翻译：酸不稳定物质的药物组成
公开(公告)号：US20090208575A1
公开(公告)日：2009-08-20
申请号：US11794748
申请日：2006-01-03
申请人： Jyothi Lakshmi Gunupati , Suryakumar Jayanthi , Himadri Sen
发明人： Jyothi Lakshmi Gunupati , Suryakumar Jayanthi , Himadri Sen
IPC分类号： A61K9/30 , A61K31/4439
CPC分类号： A61K31/133 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K31/4439 , A61K2300/00
摘要： A pharmaceutical composition for oral use comprising a) a core comprising an effective amount of benzimidazole and an organic stabilizing agent which is present in an amount effective to stabilize the composition, b) an intermediate layer comprising of a water insoluble polymer and an organic stabilizer, and c) an outer enteric coating layer. The organic stabilizing agent is present in the core from about 1% to about 10% by weight of the core and in the intermediate layer from about 5% to about 35% by weight of intermediate layer.
摘要翻译：一种用于口服使用的药物组合物，其包含a）包含有效量的苯并咪唑和有效稳定组合物的有机稳定剂的核心，b）包含水不溶性聚合物和有机稳定剂的中间层，和c）外肠衣层。有机稳定剂在核心中以核心的约1重量％至约10重量％存在，中间层中存在约5重量％至约35重量％的中间层。

4. 发明申请

US20050084455A1 Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof 审中-公开
标题翻译：用于结核分枝杆菌靶向特异性药物递送的可吸入的可生物降解微粒及其制备方法
公开(公告)号：US20050084455A1
公开(公告)日：2005-04-21
申请号：US10685567
申请日：2003-10-16
申请人： Himadri Sen , Suryakumar Jayanthi , Rakesh Sinha , Rolee Sharma , Pawan Muttil
发明人： Himadri Sen , Suryakumar Jayanthi , Rakesh Sinha , Rolee Sharma , Pawan Muttil
IPC分类号： A61K9/00 , A61K9/16 , A61K31/00 , A61K31/445 , A61K31/455 , A61L9/04 , A61K9/14 , A61K31/496
CPC分类号： A61K9/0075 , A61K9/0053 , A61K9/1647 , A61K31/00 , A61K31/445 , A61K31/455
摘要： The present invention relates to a biodegradable microparticle composition useful for the target specific drug delivery to manage pulmonary tuberculosis, said composition comprising two anti-tuberculosis drugs, and a biodegradable polymer for drug delivery in a ratio of about 1:2 to 2:1, wherein the anti-tubercular drugs are in the ratio of 1:2 to 2:1, also, a process for the preparation of the composition, and lastly, a method of treating pulmonary tuberculosis in a subject, said method comprising administering by inhalation alone or in combination with oral route, pharmaceutically effective amount of the composition to the subject in need thereof, wherein the dosage for inhalation is ranging between 0.5 to 10 mg/kg body weight/day and that for oral route is ranging between 4 to 32 mg/kg body weight/day.
摘要翻译：本发明涉及可用于目标特异性药物递送以管理肺结核的可生物降解的微粒组合物，所述组合物包含两种抗结核药物和用于药物递送的生物可降解聚合物，其比例为约1:2至2:1，其中抗结核药物的比例为1:2至2:1，也是制备组合物的方法，最后是治疗受试者肺结核的方法，所述方法包括单独给药或与口服途径组合的药物有效量的组合物与有需要的受试者组合，其中吸入剂量为0.5至10mg / kg体重/天，口服途径的范围为4至32mg / kg体重/天。

5. 发明申请

US20100055181A1 CONTROLLED RELEASE DOSAGE FORMS OF ZOLPIDEM 审中-公开
标题翻译：控制释放剂量的ZOLPIDEM
公开(公告)号：US20100055181A1
公开(公告)日：2010-03-04
申请号：US12517487
申请日：2007-02-07
申请人： Nilesh Bhandari , Vineeth Raghavan , Surya Kumar Jayanthi , Himadri Sen
发明人： Nilesh Bhandari , Vineeth Raghavan , Surya Kumar Jayanthi , Himadri Sen
IPC分类号： A61K9/32 , A61K31/437 , A61K9/20 , A61K9/10 , A61K9/16
CPC分类号： A61K9/2054 , A61K9/0004 , A61K9/209 , A61K9/5047 , A61K9/5078
摘要： A controlled release dosage forms comprising zolpidem or a salt thereof to release zolpidem to induce rapid onset of sleep, and continue to release zolpidem in a controlled manner to maintain effective plasma concentrations over an extended period of time to improve sleep maintenance. The pharmaceutical controlled-release dosage form of zolpidem or a salt thereof having a dissolution profile when measured in a type I or II dissolution apparatus according to the U.S. Pharmacopoeia in 0.01M hydrochloric acid buffer at 37° C., such that less than 40% is released at the end of 30 minutes.
摘要翻译：包含唑吡旦或其盐的控制释放剂型，以释放唑吡旦以诱发快速睡眠发作，并以受控的方式继续释放唑吡旦，以在更长的时间内维持有效的血浆浓度以改善睡眠维持。当在0.01M盐酸缓冲液中在37℃下按照美国药典在I型或II型溶出装置中测量时，唑吡旦或其盐的药物控制释放剂型具有溶出曲线，使得小于40％在30分钟结束时发布。

6. 发明申请

US20050031685A1 Pharmaceutical composition for controlled release of a beta-lactam antibiotic 有权
标题翻译：用于控释β-内酰胺抗生素的药物组合物
公开(公告)号：US20050031685A1
公开(公告)日：2005-02-10
申请号：US10495961
申请日：2001-11-19
申请人： Himadri Sen , Rajesh Kshirsagar , Shailesh Bhamare
发明人： Himadri Sen , Rajesh Kshirsagar , Shailesh Bhamare
IPC分类号： A61K9/20 , A61K9/22 , A61K9/24 , A61K31/24 , A61K31/545 , A61K33/06
CPC分类号： A61K31/545 , A61K9/2009 , A61K9/2018 , A61K9/205 , A61K9/2054 , A61K9/209 , A61K31/24 , A61K33/06 , Y10S514/964 , A61K2300/00
摘要： An improved stable pharmaceutical composition for controlled release of an active ingredient comprises a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters as active ingredient, a calcium salt and a mixture of hydrophilic polymers selected from the group consisting of at least one sodium alginate and one xanthan gum and with or without hydroxypropyl methylcellulose, said composition optionally containing probenecid. The composition may also contain one or more of a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymers and water soluble and/or water dispersible diluents are such that the therapeutically effective active ingredient is released at a rate suitable for once or twice daily administration of the pharmaceutical composition.
摘要翻译：用于控制释放活性成分的改进的稳定药物组合物包括β-内酰胺抗生素如头孢氨苄，头孢克洛或其药学上可接受的水合物，作为活性成分的盐或酯，钙盐和亲水性聚合物的混合物，所述亲水性聚合物选自至少一种藻酸钠和一种黄原胶，以及含或不含羟丙基甲基纤维素，所述组合物任选地含有丙磺舒。组合物还可以含有一种或多种水溶性和/或水分散性稀释剂，其中亲水性聚合物和水溶性和/或水分散性稀释剂的量使得治疗有效的活性成分以适合于每天一次或两次给药药物组合物。

7. 发明授权

US6074669A Controlled drug delivery system for diltiazem 失效
标题翻译：地尔硫卓治疗药物输送系统
公开(公告)号：US6074669A
公开(公告)日：2000-06-13
申请号：US984733
申请日：1997-12-04
申请人： Vishnubhotla Nagaprasad , Himadri Sen
发明人： Vishnubhotla Nagaprasad , Himadri Sen
IPC分类号： A61K9/20 , A61K9/26 , A61K9/52
CPC分类号： A61K9/2054
摘要： A pharmaceutical composition in the form of a tablet or a capsule for the controlled release of diltiazem, comprises about 30 to about 97% by weight of a hydrophilic polymer, about 0.5 to about 30% by weight of an enteric (pH-dependent) polymer, and about 2.5 to about 60% by weight of diltiazem or a pharmaceutically acceptable salt or ester thereof. The ratio of hydrophilic polymer to enteric polymer is in the range of about 1:1 to about 15:1. Such a pharmaceutical composition releases diltiazem at a rate that allows effective plasma levels of diltiazem to be maintained over a period of twenty-four hours after administration to human adult subjects.
摘要翻译：片剂或胶囊形式的用于控制地尔硫卓的药物组合物包含约30至约97重量％的亲水性聚合物，约0.5至约30重量％的肠溶（pH依赖性）聚合物，和约2.5至约60重量％的地尔硫卓或其药学上可接受的盐或酯。亲水性聚合物与肠溶性聚合物的比率在约1:1至约15:1的范围内。这样的药物组合物以给予人成年受试者的二十四小时内维持有效血浆水平的地尔硫卓的速度释放地尔硫卓。

8. 发明申请

US20100009955A1 PHARMACEUTICAL COMPOSITIONS OF CEFIXIME 有权
标题翻译： CEFIXIME的药物组合物
公开(公告)号：US20100009955A1
公开(公告)日：2010-01-14
申请号：US12297026
申请日：2007-03-23
申请人： Sanjay Chhagan Wagh , Bharat Raghunath Metkar , Makarand Krishnakumar Avachat , Himadri Sen
发明人： Sanjay Chhagan Wagh , Bharat Raghunath Metkar , Makarand Krishnakumar Avachat , Himadri Sen
IPC分类号： A61K31/546 , A61P31/04
CPC分类号： A61K9/10 , A61K9/0095 , A61K31/43 , A61K31/545 , A61K31/546 , Y10S514/97
摘要： A pharmaceutical suspension formulation comprising a dose greater than 100 mg/5 ml Cefixime and pharmaceutically acceptable excipients.
摘要翻译：包含剂量大于100mg / 5ml的头孢克肟和药学上可接受的赋形剂的药物悬浮液制剂。

9. 发明申请

US20090304755A1 PHARMACEUTICAL FORMULATION OF LOSARTAN 审中-公开
标题翻译：洛萨坦的药物制剂
公开(公告)号：US20090304755A1
公开(公告)日：2009-12-10
申请号：US12091852
申请日：2006-01-06
申请人： Raghu Rami Reddy Kasu , Dhanashree Mistry , Sunderraj Manvi , Vijaya Kumar Thommandru , Himadri Sen
发明人： Raghu Rami Reddy Kasu , Dhanashree Mistry , Sunderraj Manvi , Vijaya Kumar Thommandru , Himadri Sen
IPC分类号： A61K9/00 , A61K31/5415 , A61P9/12
CPC分类号： A61K9/2077 , A61K9/2866 , A61K31/4178 , A61K31/54 , C07D403/10 , A61K2300/00
摘要： A pharmaceutical composition comprising losartan and pharmaceutically acceptable salts thereof and a process of forming the same. The pharmaceutical composition of losartan comprises an active agent comprising an effective amount of losartan or its pharmaceutical salt thereof, and pharmaceutically acceptable additives, wherein d(0.9) of losartan is less than 50μ and/or specific surface area is more than 0.6 m2/gm. The process of preparation of pharmaceutical composition of losartan, comprises the steps of blending the losartan having d(0.9) less than 50μ and/or specific surface area more than 0.6 m2/gm, with the other intragranular excipients, dry compression, milling and screening to obtain granules, said granules being subsequently blended with extragranular excipients and compressed to tablets which is further coated.
摘要翻译：包含氯沙坦及其药学上可接受的盐的药物组合物及其形成方法。氯沙坦的药物组合物包含有效量的氯沙坦或其药用盐和药学上可接受的添加剂的活性剂，其中d（0.9）的氯沙坦小于50mu，和/或比表面积大于0.6m 2 / gm 。制备氯沙坦药物组合物的方法包括将d（0.9）小于50mu和/或比表面积大于0.6m 2 / gm的氯沙坦与其它颗粒内赋形剂，干压缩，研磨和筛选为了获得颗粒，所述颗粒随后与颗粒外赋形剂混合并压制成进一步包被的片剂。

10. 发明申请

US20050175694A1 Long acting compositions comprising zidovudine and lamivudine 审中-公开
标题翻译：包含齐多夫定和拉米夫定的长效组合物
公开(公告)号：US20050175694A1
公开(公告)日：2005-08-11
申请号：US10512464
申请日：2002-04-23
申请人： Himadri Sen , Surva Jayanthi
发明人： Himadri Sen , Surva Jayanthi
IPC分类号： A61K9/20 , A61K9/22 , A61K31/7068 , A61K31/7072 , A61P31/18
CPC分类号： A61K9/205 , A61K9/2054 , A61K9/2059 , A61K31/7068 , A61K31/7072 , A61K2300/00
摘要： A pharmaceutical composition in the form of a tablet for controlled release of active ingredient(s) comprises lamivudione, zidovudine or combination of lamivudine and zidovudine or their pharmaceutically acceptable derivatives, and a mixture of hydrophilic polymers selected from the group consisting of at least one hydroxypropyl methylcellulose, at least one sodium alginate and at least one guar gum as controlled release matrix and a pharmaceutically acceptable calcium salt as a matrix stabilizer. The composition may also contain one or more of a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymers, the calcium salt and water soluble and/or water dispersible diluents are such that the therapeutically effective active ingredient(s) is released at a rate suitable for once daily administration of the pharmaceutical composition. The tablets may be coated with a water soluble polymeric film coat.
摘要翻译：用于控制释放活性成分的片剂形式的药物组合物包括拉米夫定，齐多夫定或拉米夫定和齐多夫定或其药学上可接受的衍生物的组合，以及选自至少一种羟丙基甲基纤维素，至少一种藻酸钠和至少一种瓜尔胶作为控释基质和药学上可接受的钙盐作为基质稳定剂。组合物还可以含有一种或多种水溶性和/或水分散性稀释剂，其中亲水性聚合物，钙盐和水溶性和/或水分散性稀释剂的量使得治疗有效的活性成分以适合于每日一次给予药物组合物的速率释放。片剂可以用水溶性聚合物膜包衣包衣。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式